Great Basin Welcomes Kirk Calhoun to Board of Directors

SALT LAKE CITY, June 2, 2015 /PRNewswire/ -- Great Basin Scientific, Inc. GBSN GBSNU), a molecular diagnostics company, today announced the election of Kirk Calhoun to its Board of Directors, effective May 27, 2015. Mr. Calhoun was elected to the board as an independent director during the Company's Annual Stockholder Meeting on May 27 in Salt Lake City. He will serve as the chair of the Company's Audit Committee. Mr. Calhoun joins Ryan Ashton, David Spafford, Ronald K. Labrum and Sam Chawla on the board, and replaces Steven Aldous, who is retiring from his director position.

"Following a broad search for a professional with experience that would further strengthen our board's breadth of talent and background, we are delighted to have identified such an outstanding individual in Kirk Calhoun," said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin. "Kirk's strong experience in finance, corporate governance and his service on the Boards of other life sciences companies will be extremely valuable as Great Basin continues pursuing its growth strategy."

"On behalf of our board and the management team, I would like to offer our sincere appreciation to Steve Aldous for his important contributions to Great Basin during our early growth phase," Ashton continued.

Mr. Calhoun is a Certified Public Accountant (non-practicing) with a background in auditing and accounting. Mr. Calhoun joined Ernst & Young LLP, a public accounting firm, in 1965 and served as a partner of the firm from 1975 until his retirement in 2002. Mr. Calhoun currently serves on the board and audit committee of Response Genetics, Inc. RGDX and Ryerson Holding Corporation RYI. Mr. Calhoun has served previously on the boards and audit committees of five public companies in the pharmaceutical industry up until the dates of their respective sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc. and Adams Respiratory Therapeutics, Inc.  Mr. Calhoun also currently serves on the boards of three private companies, including NeuroSigma, Inc., a developer of products that treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Mr. Calhoun received a B.S. in Accounting from the University of Southern California.

About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies.  The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com. 

Forward-Looking Statements
This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2014.  These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

Media Contact:
Kate Ottavio Kent
ICR
203.682.8276
Kate.Ottavio-Kent@icrinc.com

Investor Relations Contact:
Bob Yedid
ICR
646.277.1250
bob.yedid@icrinc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/great-basin-welcomes-kirk-calhoun-to-board-of-directors-300092108.html

SOURCE Great Basin Scientific, Inc.